SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Monogram Orthopaedics, Inc. (MGRM) , forward earnings yield 3.50%.
Criteria proven by this page:
- VALUE (35/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
- Forward P/E 28.6
- Analyst consensus target $5.40 (-10% downside) — slight downside risk — the market may be ahead of analyst expectations.
Overall SharesGrow Score: 44/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
35/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — MGRM
Valuation Multiples
P/E (TTM)0.0
Forward P/E28.6
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.50
Forward EPS (Est.)$0.21
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Forward Earnings Yield3.50%
Dividend Yield0.00%
Analyst Target$5.40 (-10%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2017 |
$-0.02 |
$0.00 |
$-659K |
- |
| 2018 |
$-0.02 |
$0.00 |
$-712.27K |
- |
| 2019 |
$-0.06 |
$0.00 |
$-1.8M |
- |
| 2020 |
$-0.31 |
$0.00 |
$-9.07M |
- |
| 2021 |
$-0.40 |
$628.25K |
$-11.81M |
-1880.6% |
| 2022 |
$-0.47 |
$0.00 |
$-13.69M |
- |
| 2023 |
$-0.61 |
$365K |
$-13.75M |
-3765.8% |
| 2024 |
$-0.50 |
$0.00 |
$-16.33M |
- |
